Waypoint Capital Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Waypoint Capital Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-90,989	Closed	-$2.3M	–	136
2023 Q2	$2.3M	Hold	90,989	–	–	0.72%	39
2023 Q1	$2.93M	Buy	90,989 +37,000	+69%	+$1.15M	0.95%	32
2022 Q4	$997K	Buy	+53,989	New	+$1.23M	0.35%	63
2022 Q2	–	Sell	-53,989	Closed	-$1.02M	–	142
2022 Q1	$1.02M	Buy	+53,989	New	+$819K	0.6%	44

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Waypoint Capital Advisors's RVNC Position: Q3 2023 in Review

Waypoint Capital Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 90,989 shares — an estimated $2.3M sold.

Waypoint Capital Advisors first reported a position in RVNC in Q1 2022 and held it in 4 quarters. The position peaked at $2.93M in Q1 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

Waypoint Capital Advisors reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
Waypoint Capital Advisors sold 90,989 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $2.3M.
Waypoint Capital Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2022 and held it in 4 quarters.
Waypoint Capital Advisors's Revance Therapeutics, Inc. position peaked at $2.93M in Q1 2023.
186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Waypoint Capital Advisors's 13F filing for Q3 2023, filed 25 Oct 2023.